Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352558 · ClinicalTrials.gov registry record · Phase 1
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02352558 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 15 participants.
The verdict
NCT02352558, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
Interventions
- DRUG Dexamethasone
- DRUG Ibrutinib
- DRUG Bortezomib
- DRUG Imatinib
- DRUG BBI608
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352558
The ClinicalTrials.gov registry entry for NCT02352558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT02352558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02352558 about?
NCT02352558 is a clinical study titled "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies". This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
What is the current status of trial NCT02352558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-05. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT02352558?
The interventions under investigation include: Dexamethasone (DRUG), Ibrutinib (DRUG), Bortezomib (DRUG), Imatinib (DRUG), BBI608 (DRUG).
Who is sponsoring clinical trial NCT02352558?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.